Lanean...

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

BACKGROUND: Malignant cells of classical Hodgkin lymphoma (cHL) are characterised by genetic alterations at the 9p24·1 locus. This leads to overexpression of the programmed death 1 (PD-1) ligands and enables tumour cells to evade immune surveillance. A phase 1b study showed that nivolumab, a PD-1-bl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Oncol
Egile Nagusiak: Younes, Anas, Santoro, Armando, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M, Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B, Collins, Graham, Savage, Kerry J, Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto, Parker, Susan M, Rodig, Scott, Roemer, Margaretha GM, Ligon, Azra H, Engert, Andreas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5541855/
https://ncbi.nlm.nih.gov/pubmed/27451390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30167-X
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!